Skip to main content

NEWSBRIEF: Strong Sales Boost Beckman Coulter s Q1 Profit; R&D Static

NEW YORK, April 29 - Beckman Coulter today said first-quarter profit rose nearly 20 percent as sales improved for its robotic automation and genetic analysis tools.

Sales for the period ended March 31 climbed 3.2 percent to $446.7 million as sales increased in the Americas and Europe. Sales declined in Asia, however.

Net earnings were $28 million, or $.43 per share, compared with $23.4 million, or $.37 per share, one year ago, Beckman said.  


The company added that second-quarter sales will grow 6 percent.

R&D spending, meanwhile, was static year over year at about $42 million. However, Beckman's cash and cash equivalents as of March 31 were $35 million, off slightly from the $36 million it posted one year ago, the firm said.

 

For more information, readers may click here.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.